STOCK TITAN

Zenas BioPharma (ZBIO) awards options and ESPP shares to officer

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Zenas BioPharma, Inc. reported that officer Jennifer A. Fox received equity awards in the form of an option grant and common shares. On June 15, 2026, she was granted 125,000 stock options to buy common stock at $18.71 per share, expiring on June 15, 2036. The option vests 25% on June 15, 2027, then in equal monthly installments over the following 36 months, subject to continued service. On February 5, 2026, she also acquired 1,592 common shares at $13.35 under the company’s 2024 Employee Stock Purchase Plan in transactions exempt under Rule 16b-3(c).

Positive

  • None.

Negative

  • None.
Insider Fox Jennifer A.
Role See Remarks
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 125,000 $0.00 --
Grant/Award Common Stock 1,592 $13.35 $21K
Holdings After Transaction: Stock Option (Right to Buy) — 125,000 shares (Direct, null); Common Stock — 1,592 shares (Direct, null)
Footnotes (1)
  1. Common Stock acquired under Zenas BioPharma, Inc.'s 2024 Employee Stock Purchase Plan on February 5, 2026 in transactions that were exempt under Rule 16b-3(c). The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.
Option grant size 125,000 options Granted June 15, 2026 to buy common stock
Option exercise price $18.71 per share Stock option strike price
Option expiration June 15, 2036 Stock option term end date
ESPP shares acquired 1,592 shares Common stock acquired February 5, 2026
ESPP purchase price $13.35 per share Common stock under 2024 Employee Stock Purchase Plan
Employee Stock Purchase Plan financial
"Common Stock acquired under Zenas BioPharma, Inc.'s 2024 Employee Stock Purchase Plan on February 5, 2026"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Rule 16b-3(c) regulatory
"in transactions that were exempt under Rule 16b-3(c)"
An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.
stock option financial
"The option vests as to 25% of the underlying shares of common stock"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vesting commencement date financial
"the first anniversary of the vesting commencement date, and as to the remaining shares"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fox Jennifer A.

(Last)(First)(Middle)
C/O ZENAS BIOPHARMA, INC.
852 WINTER ST., SUITE 250

(Street)
WALTHAM MASSACHUSETTS 02451

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Zenas BioPharma, Inc. [ ZBIO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock02/05/2026AV1,592A$13.351,592(1)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$18.7106/15/2026A125,000 (2)06/15/2036Common Stock125,000$0125,000D
Explanation of Responses:
1. Common Stock acquired under Zenas BioPharma, Inc.'s 2024 Employee Stock Purchase Plan on February 5, 2026 in transactions that were exempt under Rule 16b-3(c).
2. The option vests as to 25% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.
Remarks:
Chief Business Officer and Chief Financial Officer
By: /s/ Jeffrey Held, Attorney-in-Fact06/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Jennifer A. Fox report acquiring in ZBIO Form 4?

Jennifer A. Fox reported a grant of 125,000 stock options and an acquisition of 1,592 common shares. The options have a $18.71 exercise price, while the shares were acquired at $13.35 under Zenas BioPharma’s 2024 Employee Stock Purchase Plan.

What are the terms of Jennifer A. Fox’s 125,000 Zenas BioPharma stock options?

Fox’s 125,000 stock options allow her to buy common stock at $18.71 per share and expire June 15, 2036. They vest 25% on June 15, 2027, then in equal monthly installments over 36 months, contingent on her continued service.

How many Zenas BioPharma common shares does Jennifer A. Fox hold after the ESPP transaction?

After the Employee Stock Purchase Plan transaction on February 5, 2026, Fox directly holds 1,592 common shares. These shares were acquired at $13.35 per share in a transaction treated as exempt under Rule 16b-3(c).

When do Jennifer A. Fox’s Zenas BioPharma stock options expire and start vesting?

The 125,000 stock options expire on June 15, 2036. Vesting begins June 15, 2027, when 25% of the underlying shares vest, with the remaining shares vesting in equal monthly installments over the next 36 months, subject to continued service.

What is the nature of Jennifer A. Fox’s February 5, 2026 ZBIO stock acquisition?

On February 5, 2026, Fox acquired 1,592 Zenas BioPharma common shares at $13.35 per share through the 2024 Employee Stock Purchase Plan. The filing notes the transaction was exempt under Rule 16b-3(c), indicating a compensation-related acquisition rather than an open-market trade.